We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Lab-on-a-Chip Approach Advances Immune–Cancer Cell Interaction Analysis

By HospiMedica International staff writers
Posted on 19 Jun 2026

Conventional cytotoxicity assays often average responses across thousands of cells, obscuring how individual immune cells engage and kill tumor cells. More...

For immunotherapy evaluation, the precise sequence of cell contact, activation, and later tumor-cell death can be decisive, but is rarely captured in standard workflows. Single-cell, time-based readouts remain challenging in many laboratories. Researchers now present an instrument-free lab-on-a-chip approach that visualizes immune–cancer cell interactions over time in high detail.

At the Technical University of Munich (TUM), investigators developed CellTrap, a microfluidic lab-on-a-chip platform designed to study discrete cell-to-cell contacts. The device features a large main channel that branches into 1,024 trapping chambers, where individual immune cells and cancer cells can be co-localized and immobilized. These interactions are then tracked by time-lapse microscopy for up to 14 hours, enabling continuous observation of contact formation, immune activation, and target-cell killing. The platform supports diverse experimental contexts, including cancer cells alone, immune cells alone, and varied immune-to-cancer cell ratios, while operating on a standard fluorescence microscope without specialized equipment.

Initial experiments using a glioblastoma cell line showed that tumor cells were attacked more frequently and intensely when several immune cells encountered a single target. The observations also indicated that early activation signals in immune cells often foreshadowed later cell-damaging effects, linking initiation events to outcomes within the same interaction. Beyond glioblastoma, CellTrap was tested with two additional cancer cell lines, chronic myeloid leukemia and adenocarcinoma, demonstrating applicability across different tumor contexts.

Details of the work are published in RSC Advances on April 10, 2026, under the title “CellTrap: an instrument-free microfluidic platform for cell–cell interactions at stochastically generated effector-to-target ratios.” The authors highlight that the approach enables direct visualization of how early cellular responses relate to later consequences in individual pairings, information that is typically inaccessible in bulk assays. The platform’s design emphasizes simplicity and affordability by leveraging existing fluorescence microscopy infrastructure commonly available in research labs.

“With CellTrap, we can not only measure whether immune cells kill cancer cells, but also track when and under what conditions this occurs. This matters, because immune responses can vary so much from one cell to the next. And we deliberately kept the platform simple and affordable: it runs on a standard fluorescence microscope of the kind most labs already have, with no specialised equipment,” said Ghulam Destgeer, Professor of Control and Manipulation of Microscale Living Objects at the TUM School of Computation, Information and Technology.

“The more we learn about what actually happens between individual cells, the better we can compare treatment strategies and develop new ones. And although we focused on immune and cancer cells, the platform isn’t limited to them — almost any combination of cells can be loaded and observed in the chip,” said Destgeer.

Related Links
TUM


Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Blood Pressure Monitor
Cuff Blood Pressure Monitor
Gold Member
Blood Gas Analyzer
i-Check200
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Medical Imaging

view channel
Images from patient T1, who had menstrual cycle–dependent right shoulder pain. (A) Maximum-intensity-projection images show abnormal findings for right diaphragm (arrowhead), bilateral round ligaments, peritoneum around bilateral ovaries, and left fallopian tube. Combined PET/MRI show hyperintense lesion with focal uptake inferior of right diaphragm, indicative of endometriosis (arrowhead, B). Confirmatory laparoscopy demonstrated extensive pelvic disease and implants of right diaphragm (C) that stained intensely positive for FAP (D).  (Image Credit: Schindler P, Brandt J, Bobe S, et al. Initial results of FAPI PET/MRI to assess the extent of endometriosis. J Nucl Med. 2026;67(8):1232–1238. doi:10.2967/jnumed.125.271376)

Targeted PET/MRI Improves Detection and Preoperative Mapping of Endometriosis

Endometriosis is a chronic inflammatory condition in which endometrial-like tissue grows outside the uterus, causing pelvic pain, infertility, and reduced quality of life. Conventional imaging can underestimate... Read more

Business

view channel
Image: Sempresto’s Smartphone-Integrated Epinephrine Auto-Injector Wins Red Dot Design Award (Photo courtesy of Sempresto)

Smartphone-Integrated Epinephrine Auto-Injector Concept Wins Red Dot Design Award

Severe allergic reactions can escalate rapidly and require prompt epinephrine, yet many at-risk patients do not consistently carry their auto-injector. With food allergies affecting an estimated 220 million... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.